Shanghai Tehua Pharmaceutical

Shanghai Tehua Pharmaceutical (Topharman) is a China-based biopharmaceutical company specializing in the discovery and development of innovative small molecule drugs, particularly in the fields of neuropsychiatry, viral infections, and reproductive health. Founded in 2000 and headquartered in Shanghai, the company operates as both an innovative drug developer and a high-end pharmaceutical service provider (CRO/CDMO). Its pipeline includes notable candidates such as TPN171 (Tunodafil) for erectile dysfunction and pulmonary arterial hypertension, and VV116, an oral anti-SARS-CoV-2 nucleoside analog. Topharman is recognized for its strong collaboration with the Shanghai Institute of Materia Medica (SIMM) and its expertise in complex chemical synthesis and process optimization.